Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

biomarkers

Celgene building

Celgene takes aim at cancer innovation with new US research consortium

Academic tie-up aims to develop new therapeutics and diagnostics

National Institute for Health and Care Excellence NICE logo

NICE backs five new drugs after discounts agreed

Includes Novartis’ previously rejected lung cancer and melanoma therapies Zykadia and Mekinist

- PMLiVE

GSK’s triple COPD therapy tops Symbicort in phase III trial

Once-daily, single inhaler combination treatment showed “significant” improvement in lung function

- PMLiVE

Ariad files early marketing application for brigatinib

Second-line lung cancer therapy could be on the market by early 2017

- PMLiVE

Trial backs Keytruda use first-line in lung cancer

Suggests Merck & Co’s drug is more effective than chemotherapy for NSCLC patients

Sanofi reception

Sanofi moves to replace Medivation board

Ramps up efforts to seize control of its US biopharma takeover target

Roche Basel Switzerland

Roche gets EU okay for Avastin/Tarceva combination

Lung cancer therapy ‘significantly’ extends progression-free survival

China drug medicine pharma prices

Cancer drugs “less affordable in low-income countries”

China and India are among those hit hardest by the rapidly escalating price of therapies

- PMLiVE

Trial of AbbVie’s Rova-T disappoints at ASCO

But company says the modest trial data is “a good early sign” for lung cancer drug

- PMLiVE

AstraZeneca to develop Lynparza companion diagnostic

Will collaborate with Foundation Medicine on test for its ovarian cancer drug

- PMLiVE

Biosimilar trastuzumab comparable to brand, ASCO hears

Roche’s Herceptin matched in safety and efficacy by Mylan and Biocon’s breast cancer drug

Roche Basel Switzerland

Roche’s Tecentriq works as first-line bladder cancer therapy

New trial data presented at ASCO supports wider use of the drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links